Tiziana Life Sciences announces findings from nasal anti-CD3 mAb treatment

Tiziana Life Sciences announced broad-based findings on the utility of nasal anti-CD3 mAb in the treatment of intracerebral hemorrhage, ICH. The data using a mouse model of collagenase-induced ICH was presented at the Annual American Academy of Neurology conference. "The comprehensive and consistent findings of Dr. Izzy’s research strongly supports the promising role of intranasal foralumab, the only fully human anti-CD3 monoclonal antibody, and its potential for broad applications in neuroinflammation, including the treatment of acute ICH," said Gabriele Cerrone, Executive Chairman, Founder, and interim Chief Executive Officer of Tiziana. "These exciting findings may allow Tiziana to explore additional intranasal foralumab neuroinflammatory indications to help patients with unmet needs and create further shareholder value".